Bleeding complications in patients with hematologic malignancies

Seminars in Thrombosis and Hemostasis

Volumn 39, Issue 1, 2013, Pages 94-100

  Franchini, Massimo ^a   Frattini, Francesco ^a   Crestani, Silvia ^a   Bonfanti, Carlo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

bleeding; hematologic malignancies; leukemia; therapy

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ASPARAGINASE; AUTOANTIBODY; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FIBRINOGEN; FRESH FROZEN PLASMA; MERCAPTOPURINE; MYCOPHENOLIC ACID; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RETINOIC ACID; RITUXIMAB; THROMBOCYTE CONCENTRATE; THYMOCYTE ANTIBODY; TRANEXAMIC ACID; VINCRISTINE;

ACUTE LEUKEMIA; APLASTIC ANEMIA; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CRYOPRECIPITATE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMARTHROSIS; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; LIVER DYSFUNCTION; LUNG HEMORRHAGE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PATHOGENESIS; PLASMAPHERESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOSIS; VASCULAR DISEASE; VON WILLEBRAND DISEASE;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGE; HUMANS; LEUKEMIA; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 84873412209     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1331154     Document Type: Review

References (79)

1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A., ed. Clinique Medicinale de l'Hotel-Dieu de Paris. Paris, France JB Bailliere et fils: 1865; 645 712
2. Franchini M., Montagnana M., Targher G., Manzato F., Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis: 2007; 24 1 29 38
3. Franchini M., Mannucci P. M. Thrombin and cancer: from molecular basis to therapeutic implications. Semin Thromb Hemost: 2012; 38 1 95 101
4. Bick R. L. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost: 1992; 18 4 353 372
5. Bick R. L., Strauss J. F., Frenkel E. P. Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am: 1996; 10 4 875 907
6. Rickles F. R., Falanga A., Montesinos P., Sanz M. A., Brenner B., Barbui T. Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? Thromb Res: 2007; 120 02 S99 S106
7. Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost: 2007; 33 4 427 434
8. Carlson K. S., DeSancho M. T. Hematological issues in critically ill patients with cancer. Crit Care Clin: 2010; 26 1 107 132
9. Athale U. H., Chan A. KC. Hemorrhagic complications in pediatric hematologic malignancies. Semin Thromb Hemost: 2007; 33 4 408 415
10. Slichter S. J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev: 2004; 18 3 153 167
11. Slichter S. J. Evidence based platelet transfusion guidelines. Hematology (Am Soc Hematol Educ Program): 2007; 172 178
12. Heckman K. D., Weiner G. J., Davis C. S., Strauss R. G., Jones M. P., Burns C. P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol: 1997; 15 3 1143 1149
13. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med: 1997; 337 26 1870 1875
14. Zumberg M. S., del Rosario M. L., Nejame C. F., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant: 2002; 8 10 569 576
15. Diedrich B., Remberger M., Shanwell A., Svahn B. M., Ringdén O. A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 × 10(9) per L versus 30 × 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion: 2005; 45 7 1064 1072
16. Slichter S. J. Platelet transfusion therapy. Hematol Oncol Clin North Am: 2007; 21 4 697 729, vii
17. Estcourt L. J., Stanworth S. J., Murphy M. F. Platelet transfusions for patients with haematological malignancies: who needs them? Br J Haematol: 2011; 154 4 425 440
18. British Committee for Standards in Haematology, Blood Transfusion Task Force Guidelines for the use of platelet transfusions. Br J Haematol: 2003; 122 1 10 23
19. Slichter S. J., Kaufman R. M., Assmann S. F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med: 2010; 362 7 600 613
20. Estcourt L. J., Stanworth S. J., Murphy M. F. Prophylactic platelet transfusions. Curr Opin Hematol: 2010; 17 5 411 417
21. Bowen D., Culligan D., Jowitt S., et al. UK MDS Guidelines Group Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol: 2003; 120 2 187 200
22. Pamphilon D. H., Aparicio S. R., Roberts B. E., Menys V. C., Tate G., Davies J. A. The myelodysplastic syndromes-a study of haemostatic function and platelet ultrastructure. Scand J Haematol: 1984; 33 5 486 491
23. Eby C., Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep: 2003; 2 5 388 394
24. Glaspy J. A. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am: 1992; 6 6 1301 1314
25. DiMinno G., Coraggio F., Cerbone A. M., et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest: 1986; 77 1 157 164
26. Adams T., Schutz L., Goldberg L. Platelet function abnormalities in the myeloproliferative disorders. Scand J Haematol: 1974; 13 3 215 224
27. Wehmeier A., Scharf R. E., Fricke S., Schneider W. Bleeding and thrombosis in chronic myeloproliferative disorders: relation of platelet disorders to clinical aspects of the disease. Haemostasis: 1989; 19 5 251 259
28. Papadakis E., Hoffman R., Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev: 2010; 24 6 227 232
29. Wu K. K. Platelet hyperaggregability and thrombosis in patients with thrombocythemia. Ann Intern Med: 1978; 88 1 7 11
30. Jensen M. K., de Nully Brown P., Lund B. V., Nielsen O. J., Hasselbalch H. C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol: 2000; 110 1 116 124
31. Budde U., Scharf R. E., Franke P., Hartmann-Budde K., Dent J., Ruggeri Z. M. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood: 1993; 82 6 1749 1757
32. Konkle B. A. Acquired disorders of platelet function. Hematology (Am Soc Hematol Educ Program): 2011; 2011 391 396
33. Cartoni C., Niscola P., Breccia M., et al. Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma: 2009; 50 3 387 391
34. Slats A. M., Egeler R. M., van der Does-van den Berg A., et al. Causes of death-other than progressive leukemia-in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia: 2005; 19 4 537 544
35. Zakarija A., Kwaan H. C. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost: 2007; 33 4 355 364
36. Franchini M., Veneri D., Lippi G. The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. Bone Marrow Transplant: 2007; 39 12 729 735
37. de la Serna J., Montesinos P., Vellenga E., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood: 2008; 111 7 3395 3402
38. Tallman M. S., Abutalib S. A., Altman J. K. The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost: 2007; 33 4 330 338
39. Sanz M. A., Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res: 2010; 125 02 S51 S54
40. Falanga A., Rickles F. R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol: 2003; 16 3 463 482
41. Franchini M., Di Minno M. ND, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost: 2010; 36 4 388 403
42. Tallman M. S., Lefèbvre P., Baine R. M., et al. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost: 2004; 2 8 1341 1350
43. Kwaan H. C. Double hazard of thrombophilia and bleeding in leukemia. Hematology (Am Soc Hematol Educ Program): 2007; 151 157
44. Franchini M., Gandini G., Di Paolantonio T., Mariani G. Acquired hemophilia A: a concise review. Am J Hematol: 2005; 80 1 55 63
45. Franchini M., Targher G., Montagnana M., Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta: 2008; 395 1-2 14 18
46. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood: 2008; 112 2 250 255
47. Franchini M., Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost: 2009; 35 8 806 813
48. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost: 1981; 45 3 200 203
49. Bossi P., Cabane J., Ninet J., et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med: 1998; 105 5 400 408
50. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol: 2006; 81 10 768 773
51. Sallah S., Wan J. Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer: 2001; 91 6 1067 1074
52. Sallah S., Nguyen N. P., Abdallah J. M., Hanrahan L. R. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med: 2000; 124 5 730 734
53. Franchini M., Targher G., Manzato F., Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol: 2008; 66 3 194 199
54. Coppola A., Favaloro E. J., Tufano A., Di Minno M. N., Cerbone A. M., Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost: 2012; 38 5 433 446
55. Collins P. W. Treatment of acquired hemophilia A. J Thromb Haemost: 2007; 5 5 893 900
56. Franchini M., Sassi M., Dell'Anna P., et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost: 2009; 35 1 76 80
57. Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol: 2003; 121 1 21 35
58. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol: 2007; 63 1 47 52
59. Escobar M. A. Bleeding in the patient with a malignancy: is it an acquired factor VIII inhibitor? Cancer: 2012; 118 2 312 320
60. Budde U., Bergmann F., Michiels J. J. Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost: 2002; 28 2 227 238
61. Franchini M., Lippi G. Acquired von Willebrand syndrome: an update. Am J Hematol: 2007; 82 5 368 375
62. Federici A. B., Rand J. H., Bucciarelli P., et al. Subcommittee on von Willebrand Factor Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost: 2000; 84 2 345 349
63. Federici A. B., Rand J. H., Mannucci P. M. Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders. Hematol J: 2001; 2 6 358 362
64. Federici A. B. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost: 2008; 6 4 565 568
65. Federici A. B. Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders. Semin Hematol: 2006; 43 1 01 S48 S58
66. Tiede A., Rand J. H., Budde U., Ganser A., Federici A. B. How I treat the acquired von Willebrand syndrome. Blood: 2011; 117 25 6777 6785
67. Federici A. B., Stabile F., Castaman G., Canciani M. T., Mannucci P. M. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood: 1998; 92 8 2707 2711
68. Kyle R. A., Gertz M. A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol: 1995; 32 1 45 59
69. Uprichard J., Perry D. J. Factor X deficiency. Blood Rev: 2002; 16 2 97 110
70. Greipp P. R., Kyle R. A., Bowie E. J. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol: 1981; 11 4 443 450
71. Comenzo R. L. How I treat amyloidosis. Blood: 2009; 114 15 3147 3157
72. Choufani E. B., Sanchorawala V., Ernst T., et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood: 2001; 97 6 1885 1887
73. Pihusch M. Bleeding complications after hematopoietic stem cell transplantation. Semin Hematol: 2004; 41 1 01 93 100
74. Bacigalupo A. Haemopoietic stem cell transplants: the impact of hemorrhagic complications. Blood Rev: 2003; 17 01 S6 S10
75. Gerber D. E., Segal J. B., Levy M. Y., Kane J., Jones R. J., Streiff M. B. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood: 2008; 112 3 504 510
76. Pihusch R., Salat C., Schmidt E., et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation: 2002; 74 9 1303 1309
77. Pihusch R., Salat C., Göhring P., et al. Factor XIII activity levels in patients with allogeneic haematopoietic stem cell transplantation and acute graft-versus-host disease of the gut. Br J Haematol: 2002; 117 2 469 476
78. Pihusch M., Bacigalupo A., Szer J., et al. F7BMT-1360 Trial Investigators Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost: 2005; 3 9 1935 1944
79. Kwaan H. C. Thrombosis in hematologic malignancies: risk and consequences. Int J Hematol Oncol: 2012; 1 1 9